Abstract: A 7-(4-((5-(3-bromobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
Type:
Grant
Filed:
September 1, 2023
Date of Patent:
April 23, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: Novel imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
Type:
Grant
Filed:
November 1, 2023
Date of Patent:
April 23, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
Abstract: Method of inhibiting a protein-protein interaction between Von Hippel-Lindau tumor-suppressor protein and hypoxia-inducible factor 1-alpha useful in the treatment of angiogenesis-related diseases and promoting wound healing.
Type:
Grant
Filed:
June 7, 2022
Date of Patent:
April 16, 2024
Assignees:
University of Macau, Hong Kong Baptist University
Inventors:
Chung Hang Leung, Dik Lung Ma, Ligen Lin, Guodong Li, Chung Nga Ko, Dan Li, Chao Yang
Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
Type:
Grant
Filed:
August 31, 2021
Date of Patent:
April 16, 2024
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
Abstract: A compound 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol compound, its synthesis, and its use as an anticancer, anti-inflammatory, and/or antimicrobial agent.
Type:
Grant
Filed:
December 26, 2023
Date of Patent:
April 9, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk, Fawy M. Abd El Latif
Abstract: Compounds of General Formula I may harvest electrogenerated excitons via metal-assisted delayed fluorescence (MADF). The compounds have utility in light emitting diodes and light emitting devices.
Type:
Grant
Filed:
May 11, 2021
Date of Patent:
April 2, 2024
Assignee:
Arizona Board of Regents on behalf of Arizona State University
Abstract: Provided are an organometallic compound represented by Formula 1 and an organic light-emitting device including a first compound represented by Formula 1.
Type:
Grant
Filed:
June 1, 2020
Date of Patent:
April 2, 2024
Assignee:
Samsung Display Co., Ltd.
Inventors:
Soobyung Ko, Mina Jeon, Sungbum Kim, Sujin Shin, Eunsoo Ahn, Eunyoung Lee, Jaesung Lee, Jihyung Lee, Hyunjung Lee, Junghoon Han
Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.
Type:
Grant
Filed:
May 26, 2022
Date of Patent:
April 2, 2024
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
Abstract: Compounds for treating tuberculosis and, particularly, anti-tubercular compounds that are ethyl 2-substitued-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as anti-tubercular agents are provided.
Type:
Grant
Filed:
August 23, 2023
Date of Patent:
March 26, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Katharigatta N. Venugopala, Pran Kishore Deb, Melendran Pillay, Sandeep Chandrashekharappa, Mohamed A. Morsy, Bandar Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Christophe Tratrat, Sheena Shashikanth, Vijaykumar Uppar, Basavaraj Padmashali
Abstract: The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.
Abstract: The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of ALK5 and/or ALK4 and are useful in the treatment of pulmonary fibrosis, NASH, obesity, diabetes, cancers and other inflammation.
Abstract: Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase.
Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
Type:
Grant
Filed:
May 27, 2021
Date of Patent:
March 12, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
Type:
Grant
Filed:
June 21, 2022
Date of Patent:
March 12, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Julian A. Codelli, Michael Graupe, Juan A. Guerrero, Jesse M. Jacobsen, Tetsuya Kobayashi, Jonathan William Medley, Yasamin Moazami, Leena B. Patel, Jie Xu, Suet C. Yeung
Abstract: The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.
Abstract: A phosphorescent emitter or delayed fluorescent and phosphorescent emitters represented by Formula I or Formula II, where M is platinum or palladium.
Type:
Grant
Filed:
November 19, 2020
Date of Patent:
March 12, 2024
Assignee:
Arizona Board of Regents on behalf of Arizona State University
Abstract: A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.
Type:
Grant
Filed:
January 27, 2022
Date of Patent:
March 12, 2024
Assignee:
MediciNova, Inc.
Inventors:
Kazuko Matsuda, Federico Carlos Aréjola Gaeta
Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
March 5, 2024
Assignees:
Syndax Pharmaceuticals, Inc., Vitae Pharmaceuticals, LLC
Inventors:
Gerard M. McGeehan, William H. Miller, Nicholas Paul Camp, Salvacion Cacatian, Santosh S. Kulkarni, Swapan Kumar Samanta, Virsinha Venkat Reddy
Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
March 5, 2024
Assignee:
HiberCell, Inc.
Inventors:
Johan Lindström, Lars Boukharta Persson, Madeleine Livendahl, Jenny Viklund, Tobias Ginman, Rickard Forsblom, Fredrik Rahm, Edward A. Kesicki, Kannan Karukurichi Ravi, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto